Rivaroxaban Recruiting Phase 3 Trials for Rheumatic Heart Disease Prevention

IndicationsStatusPurposePhase
RecruitingPrevention3
clinicaltrials.gov IdentifierTitleDrugs
NCT02832544INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority